Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is making significant strides in its transition from a development-stage biotechnology company to a commercial-stage entity, underscored by the FDA approval and commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). This targeted immunotherapy, approved in August 2024, addresses a critical unmet need in oncology, and its December 2025 launch has already generated $5.6 million in net revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. The company's strategic focus on first-in-class critical care products is evident across its diversified portfolio, which includes late-stage assets like Mino-Lok® and Halo-Lido, alongside a promising stem cell platform.
The commercial success of LYMPHIR™ is a pivotal milestone for Citius, as it provides the company with a revenue-generating asset in the oncology market. The drug, which targets relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL), has achieved broad payer coverage, with nearly 100% of covered commercial lives and 83% of targeted accounts either achieving formulary inclusion or under active review as of May 2026. Furthermore, an initial shipment to Europe in April 2026 signals international expansion, and positive topline results from investigator-initiated studies exploring LYMPHIR™ in combination with pembrolizumab for gynecologic cancers and pre-CAR-T therapy for diffuse large B-cell lymphoma hint at potential label expansion.
Beyond LYMPHIR™, Citius's pipeline addresses significant unmet medical needs. Mino-Lok®, a late-stage antibiotic lock solution for catheter-related bloodstream infections, has met its pivotal Phase 3 endpoints and holds Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. With no FDA-approved therapies specifically indicated to salvage infected central venous catheters, Mino-Lok® represents a potential $1.8 billion worldwide sales opportunity, according to company estimates. The company has received FDA guidance outlining a pathway to a New Drug Application submission, positioning it for a possible near-term regulatory milestone.
Halo-Lido (CITI-002), a topical formulation combining halobetasol and lidocaine for hemorrhoid relief, also targets a significant market, with approximately 10 million Americans reporting symptoms annually. Despite the prevalence, there are currently no FDA-approved prescription products for hemorrhoids, making Halo-Lido a potential first-in-class treatment if approved. The completion of a Phase 2b study in 2023 and subsequent FDA meetings indicate progress toward defining the next clinical steps.
Complementing these programs is Citius's stem cell platform, using induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS). Interim results from a proof-of-concept sheep model showed improvements in oxygenation, shock, and bacterial clearance, supporting further development. This platform adds another layer of diversification and potential upside.
The leadership team, led by co-founders Leonard Mazur and Myron Holubiak, brings decades of pharmaceutical experience, including commercialization and sales expertise, which is crucial for navigating the transition to a commercial-stage company. With LYMPHIR™ generating revenue and multiple late-stage catalysts on the horizon, Citius is strategically positioned to create value across its critical-care and oncology portfolio.
For more information, visit Citius Pharma.
